Anxiety with depression: a treatment need (Q33752505)

29 July 2017

1 reference

title

Anxiety with depression: a treatment need (English)

1 reference

29 July 2017

Rouillon F

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 July 1999

1 reference

European Neuropsychopharmacology

29 July 2017

published in

1 reference

29 July 2017

volume

9 Suppl 3

1 reference

29 July 2017

page(s)

S87-92

1 reference

Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Depressive symptoms and depressive diagnoses in a community population. Use of a new procedure for analysis of psychiatric classification

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Major depression in patients with agoraphobia and panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

A comparison of paroxetine and placebo in depressed outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Relationship of anxiety and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

1 reference

7 January 2021

Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Psychiatric reaction patterns to imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

The nationwide epidemiological study of mental disorders in korea

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Diagnosis and outcome: depression and anxiety in a general population

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Moclobemide in social phobia: a controlled dose-response trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Major depression in patients with social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Fluoxetine tenth anniversary update: the progress continues

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

1 reference

7 January 2021

The general neurotic syndrome: a coaxial diagnosis of anxiety, depression and personality disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Relationship of social phobia with other psychiatric illness

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

Social phobia: long-term treatment outcome and prediction of response--a moclobemide study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

The cross-national epidemiology of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2899%2900027-9

7 January 2021

10.1016/S0924-977X(99)00027-9

Identifiers

DOI

1 reference

29 July 2017

1 reference